Trial reportEuropean urology2025
Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial.
Trial report in European urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration.The Lancet. Oncology · 2026Pooled it
- Immunotherapy in urological cancers: new paradigms and a systematic review of clinical trials and real-world evidence.Frontiers in oncology · 2026Pooled it
- Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Peripheral monocyte ratio as a predictive biomarker for metastasis-directed therapy in prostate cancer: insights from an exploratory study.BMC cancer · 2026Trial
- Primary site- and metastasis-directed therapies in patients with metastatic prostate cancer: A narrative review.International journal of clinical oncology · 2026Review
- Oligometastatic prostate cancer - bridging the gap between localized and metastatic disease.Nature reviews. Urology · 2026Review
- Evidence for metastasis-directed therapy in oligometastatic prostate cancer.Nature reviews. Urology · 2026Article
- Article
- [Oligometastatic hormone-sensitive prostate cancer: when can less be more?]Urologie (Heidelberg, Germany) · 2026Review
- PSMA PET/CT-Guided Multimodal Therapy for Pelvic Lymph Node Positive and De Novo Low-Volume Metastatic Prostate Cancer: A Gulf Region Single-Institution Experience.Diseases (Basel, Switzerland) · 2026Article
- Radiobiotherapy in Osteosarcoma: A State-Based Educational Framework for Strategy Selection and Trial Design.Current oncology (Toronto, Ont.) · 2026Review
- [WOLVERINE, a meta-analysis on stereotactic radiotherapy of oligometastases in prostate cancer].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Optimal management of oligometastatic prostate cancer: current state and future directions.Current opinion in oncology · 2026Review
- Stereotactic body radiotherapy in patients with bone oligometastases from breast cancer - results from a European multicenter cohort study.Clinical and translational radiation oncology · 2026Article
- The Role of SBRT in Oligometastatic Prostate Cancer: Where We Are and Where We Are Heading.Life (Basel, Switzerland) · 2026Review
- Article
- Efficacy of neoadjuvant hormonal therapy combined with robot-assisted radical prostatectomy for oligometastatic prostate cancer: a multicenter retrospective study.Frontiers in oncology · 2026Article
- Round up.Indian journal of urology : IJU : journal of the Urological Society of IndiaArticle
- Recurrent prostate adenocarcinoma after radical prostatectomy: Principles of multidisciplinary management across a spectrum of disease.CA: a cancer journal for cliniciansArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
Abstract
BACKGROUND AND
objectiveOligometastatic prostate cancer (omPC) is characterized by limited metastases. We hypothesized that metastasis-directed therapy (MDT) to all sites of omPC combined with androgen deprivation therapy (ADT) would improve clinical outcomes.
methodsIn the multicenter phase 2 EXTEND trial, patients with omPC were randomized 1:1 to ADT versus MDT + ADT in two independently powered and randomized baskets, one using intermittent ADT and one using continuous ADT. The primary endpoint was progression-free survival (PFS). The secondary endpoints included radiologic PFS (rPFS) and castration resistance-free survival (CRFS). Here, the primary results of the continuous ADT basket, the combined analysis of both baskets, and translational immune correlatives are reported. KEY FINDINGS AND LIMITATIONS: From September 2018 through August 2022, 174 patients were randomized and were eligible for the primary analysis. In the continuous ADT basket (N = 87), the median PFS was 47 mo with MDT + ADT versus 22 mo with ADT (hazard ratio [HR], 0.50; one-sided p = 0.036). In the combined analysis, the median PFS was 36 mo with MDT + ADT versus 17 mo with ADT (HR, 0.45; p < 0.001). Radiologic PFS and CRFS were also superior with MDT + ADT. Durable clinical responses after MDT + ADT were associated with systemic Th1-polarizing cytokine upregulation and CD8 CONCLUSIONS AND CLINICAL IMPLICATIONS: MDT + ADT improves PFS compared with ADT in omPC patients, meriting phase 3 confirmation. Hypothesis-generating immune responses warrant mechanistic validation and future trials with T-cell-targeted immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.